Real-time acquisition of physiological and neurochemical data. OpiBud employs a miniaturised, implantable biosensor array capable of detecting multi-parameter signals, including oxygen saturation, interstitial pH, electrochemical activity, and microvascular perfusion. This enables continuous, high-fidelity monitoring of systemic biomarkers directly within tissue, providing data resolution impossible to achieve through surface wearables.

The OpiBud system is proposed to collect, process, and interpret multidimensional biosensor data to generate actionable insights. This would include detecting poly-drug use, screening for lethal compounds such as fentanyl analogues, and using historical usage patterns to model individual tolerance thresholds. Through longitudinal data analysis, the AI could begin to predict risk trajectories, supporting proactive clinical intervention before crisis events occur.

OpiBud’s companion application is being designed to translate biosensor data into simplified clinical dashboards for healthcare providers. The system would automatically alert clinicians, emergency services, and approved family members when concerning trends are detected, such as relapse risk or physiological instability. Patients would also receive feedback and personalised notifications to promote engagement, awareness, and adherence to treatment.

Pharmaceutech’s long-term vision is to collaborate with naloxone developers to integrate a micro-reservoir antidote delivery mechanism within future OpiBud iterations. In such a model, the system could automatically release naloxone in response to confirmed overdose signals while simultaneously notifying emergency responders. This forward-looking feature aims to transition OpiBud from a purely monitoring system into a predictive and responsive therapeutic device.